Human kidney cells – off-target cytotoxicity

Human kidney cells – off-target cytotoxicity is not a specific molecular target or receptor, but rather a critical safety endpoint used in drug discovery and development to assess drug-induced kidney injury (DIKI). This parameter measures the unintended toxic effects of a drug candidate on renal cell populations, most commonly the proximal tubule epithelial cells, which are highly susceptible to damage due to their role in drug transport and concentration (Source: StatPearls, NBK518983). Off-target nephrotoxicity is a leading cause of drug attrition during preclinical and clinical phases, as well as a frequent reason for post-marketing black box warnings or withdrawals (Source: FDA). The kidneys are particularly vulnerable because they receive approximately 20-25% of resting cardiac output and serve as the primary route for the excretion of many drugs and their metabolites (Source: NIH, PMC3612961). Common mechanisms leading to this cytotoxicity include the induction of oxidative stress, interference with mitochondrial bioenergetics, and the inhibition of essential renal transporters. Monitoring this effect involves the use of in vitro models, such as HK-2 cells or primary human renal proximal tubule epithelial cells (RPTECs), and the measurement of specific biomarkers like KIM-1 and NGAL to predict clinical risk (Source: PubMed, PMID: 28938258).

Other names

NephrotoxicityDrug-induced kidney injury (DIKI)Renal cytotoxicityOff-target renal effectsKidney cell toxicity

Not applicable as a therapeutic mechanism; toxicological mechanisms include oxidative stress, mitochondrial dysfunction, lysosomal impairment, and activation of apoptotic pathways within renal epithelial cells.